News

Find here our press releases and most relevant news

News

Press release

- October 2, 2025

Neuraxpharm strengthens multiple sclerosis portfolio with the launch of Riulvy® (tegomil fumarate)

Announcement

- September 30, 2025

Celebrating 40 Years of Neuraxpharm Germany

Press release

- September 24, 2025

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

Press release

- September 22, 2025

Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple sclerosis

Announcement

- August 11, 2025

Neuraxpharm signs an exclusive distribution agreement with Pendopharm® for Buccolam® in Canada

Announcement

- August 7, 2025

Neuraxpharm launches its Sustainability Report for 2024

Press release

- July 23, 2025

Leriglitazone Marketing Authorization Application submitted for treatment of cerebral adrenoleukodystrophy has been validated by European Medicines Agency

Press release

- July 22, 2025

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Press release

- July 8, 2025

Neuraxpharm and Dizlin Pharmaceuticals Announce Global Strategic Co-Development Agreement Bringing Next-Generation Drug-Device Therapy to Patients with Advanced Parkinson’s Disease

Announcement

- June 12, 2025

Neuraxpharm’s Corporate Values: The Principles Guiding Our Mission in CNS Care

Announcement

- June 10, 2025

Buccolam®: expanding access, empowering care in epilepsy

Announcement

- May 30, 2025

World MS Day 2025 – Amaya’s Story: The art of Moving onwardS

Announcement

- April 30, 2025

Neuraxpharm’s evolving journey in CNS innovation reflected in updated website

Announcement

- March 26, 2025

Neuraxpharm continues to shine a light on the need for improved epilepsy management

Announcement

- March 4, 2025

Reflecting on Neuraxpharm’s journey in CNS care and innovation: a video

Announcement

- February 5, 2025

Neuraxpharm appoints Vikas Mohan Sharma as Chief Medical Officer

Announcement

- February 4, 2025

Neuraxpharm Pharmaceuticals awarded EcoVadis Silver Medal for sustainability

Press release

- January 10, 2025

ZIM Laboratories Limited and Neuraxpharm Announce Grant of Marketing Authorization for “Buprenorphine Sublingual Film” in Europe

Press release

- January 7, 2025

Neuraxpharm to further grow branded business with the acquisition of two leading narcolepsy treatments, Provigil® and Nuvigil®

Press release

- December 12, 2024

Neuraxpharm and Pharmathen enter into strategic co-development agreement to develop long-acting injectable therapies

Media Enquiries

If you are a journalist with a media enquiry, please contact the Neuraxpharm media office by filling the contact form.